Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.
Xeris Biopharma is executing a sharp revenue acceleration, with 28.7% YoY growth in 2026Q2 and gross margins expanding to 86.4%, signaling strong commercial traction and pricing power.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.06+89.5% vs $0.03 | $107M+5.5% vs $102M |
Q3 2026 Aug 6, 2026 | -$0.18-1582.7% vs $0.01 | $91M+1.0% vs $90M |
Q2 2026 May 7, 2026 | $0.01+465.0% vs -$0.00 | $82M+3.3% vs $80M |
Q2 2026 Mar 2, 2026 | $0.06+100.0% vs $0.03 | $86M+4.4% vs $82M |
Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.
Xeris Biopharma Holdings has more than doubled since my March buy rating, driven by strong Q3 results and raised guidance. XERS posted a surprise GAAP profit of $0.06 per share, $11.3M net income, and 44% revenue growth to $107.2M, exceeding expectations. Gross margins improved to 88%, and Xeris eliminated $34M of convertible notes, reducing annual interest by $3M and strengthening its balance sheet.
One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
Xeris Biopharma NASDAQ: XERS raised its 2026 revenue guidance and its 2030 outlook after third-quarter sales increased 44% year over year, driven by rapid growth in its Cushing syndrome treatment Recorlev.

Benchmark XERS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Xeris Biopharma Holdings, Inc. (XERS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.80 | $2.9B | -491.23 | 43.72% | -1.76% | -39.52% | — | |
| $101.80 | $6.63B | 25.80 | 0.5% | 17.28% | 21.72% | — | |
| $29.04 | $3.54B | 7.87 | 4.29% | 32.75% | — | — | |
| $34.92 | $1.42B | 13.92 | 17.12% | 6.67% | 27.44% | 1.36% | |
| $70.07 | $7.52B | 53.29 | 12.79% | 16.81% | 22.94% | — | |
| $21.12 | $6.74B | 48.05 | 8.05% | 4.62% | 82.23% | — |
Xeris Biopharma Holdings, Inc. (XERS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Xeris Biopharma Holdings, Inc. (XERS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 17, 2026·SEC
Jun 30, 2026·SEC
Get notified when XERS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Xeris Biopharma Holdings, Inc. (XERS) stock FAQ — growth, dividends, profitability & financials explained
Xeris Biopharma Holdings, Inc. (XERS) reported $368.3M in revenue over the trailing twelve months. Revenue was $291.8M in fiscal year 2025. That is 27048% more than the $1.1M of fiscal year 2016.
Xeris Biopharma Holdings, Inc. (XERS) grew revenue by 38.4% over the trailing twelve months, compared with the twelve months before.
No. Xeris Biopharma Holdings, Inc. (XERS) reported a net loss of $6.5M over the trailing twelve months.
Xeris Biopharma Holdings, Inc. (XERS) had a return on equity (ROE) of -39.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Xeris Biopharma Holdings, Inc. (XERS) generated $72.6M in free cash flow over the trailing twelve months.